Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus

Guided Formulation Development for a Nasal Ebola Vaccine

Jin Huk Choi, Stephen C. Schafer, Alexander Freiberg, Maria A. Croyle

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The severity and longevity of the current Ebola outbreak highlight the need for a fast-acting yet long-lasting vaccine for at-risk populations (medical personnel and rural villagers) where repeated prime-boost regimens are not feasible. While recombinant adenovirus (rAd)-based vaccines have conferred full protection against multiple strains of Ebola after a single immunization, their efficacy is impaired by pre-existing immunity (PEI) to adenovirus. To address this important issue, a panel of formulations was evaluated by an in vitro assay for their ability to protect rAd from neutralization. An amphiphilic polymer (F16, FW ∼39,000) significantly improved transgene expression in the presence of anti-Ad neutralizing antibodies (NAB) at concentrations of 5 times the 50% neutralizing dose (ND<inf>50</inf>). In vivo performance of rAd in F16 was compared with unformulated virus, virus modified with poly(ethylene) glycol (PEG), and virus incorporated into poly(lactic-co-glycolic) acid (PLGA) polymeric beads. Histochemical analysis of lung tissue revealed that F16 promoted strong levels of transgene expression in naive mice and those that were exposed to adenovirus in the nasal cavity 28 days prior to immunization. Multiparameter flow cytometry revealed that F16 induced significantly more polyfunctional antigen-specific CD8<sup>+</sup> T cells simultaneously producing IFN-γ, IL-2, and TNF-α than other test formulations. These effects were not compromised by PEI. Data from formulations that provided partial protection from challenge consistently identified specific immunological requirements necessary for protection. This approach may be useful for development of formulations for other vaccine platforms that also employ ubiquitous pathogens as carriers like the influenza virus.

Original languageEnglish (US)
Pages (from-to)2697-2711
Number of pages15
JournalMolecular Pharmaceutics
Volume12
Issue number8
DOIs
StatePublished - Aug 3 2015

Fingerprint

Ebola Vaccines
Nose
Adenoviridae
Viruses
Transgenes
Immunity
Immunization
Adenovirus Vaccines
Vaccines
CD8 Antigens
Synthetic Vaccines
Ethylene Glycol
Nasal Cavity
Neutralizing Antibodies
Orthomyxoviridae
Interleukin-2
Disease Outbreaks
Flow Cytometry
Polymers
T-Lymphocytes

Keywords

  • adenovirus serotype 5
  • Ebola virus
  • formulation
  • multifunctional CD8<sup>+</sup> T cell response
  • nasal vaccine
  • pre-existing immunity

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus : Guided Formulation Development for a Nasal Ebola Vaccine. / Choi, Jin Huk; Schafer, Stephen C.; Freiberg, Alexander; Croyle, Maria A.

In: Molecular Pharmaceutics, Vol. 12, No. 8, 03.08.2015, p. 2697-2711.

Research output: Contribution to journalArticle

@article{2517aa197e6f481e82ab2475209c41bd,
title = "Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine",
abstract = "The severity and longevity of the current Ebola outbreak highlight the need for a fast-acting yet long-lasting vaccine for at-risk populations (medical personnel and rural villagers) where repeated prime-boost regimens are not feasible. While recombinant adenovirus (rAd)-based vaccines have conferred full protection against multiple strains of Ebola after a single immunization, their efficacy is impaired by pre-existing immunity (PEI) to adenovirus. To address this important issue, a panel of formulations was evaluated by an in vitro assay for their ability to protect rAd from neutralization. An amphiphilic polymer (F16, FW ∼39,000) significantly improved transgene expression in the presence of anti-Ad neutralizing antibodies (NAB) at concentrations of 5 times the 50{\%} neutralizing dose (ND50). In vivo performance of rAd in F16 was compared with unformulated virus, virus modified with poly(ethylene) glycol (PEG), and virus incorporated into poly(lactic-co-glycolic) acid (PLGA) polymeric beads. Histochemical analysis of lung tissue revealed that F16 promoted strong levels of transgene expression in naive mice and those that were exposed to adenovirus in the nasal cavity 28 days prior to immunization. Multiparameter flow cytometry revealed that F16 induced significantly more polyfunctional antigen-specific CD8+ T cells simultaneously producing IFN-γ, IL-2, and TNF-α than other test formulations. These effects were not compromised by PEI. Data from formulations that provided partial protection from challenge consistently identified specific immunological requirements necessary for protection. This approach may be useful for development of formulations for other vaccine platforms that also employ ubiquitous pathogens as carriers like the influenza virus.",
keywords = "adenovirus serotype 5, Ebola virus, formulation, multifunctional CD8<sup>+</sup> T cell response, nasal vaccine, pre-existing immunity",
author = "Choi, {Jin Huk} and Schafer, {Stephen C.} and Alexander Freiberg and Croyle, {Maria A.}",
year = "2015",
month = "8",
day = "3",
doi = "10.1021/mp5006454",
language = "English (US)",
volume = "12",
pages = "2697--2711",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus

T2 - Guided Formulation Development for a Nasal Ebola Vaccine

AU - Choi, Jin Huk

AU - Schafer, Stephen C.

AU - Freiberg, Alexander

AU - Croyle, Maria A.

PY - 2015/8/3

Y1 - 2015/8/3

N2 - The severity and longevity of the current Ebola outbreak highlight the need for a fast-acting yet long-lasting vaccine for at-risk populations (medical personnel and rural villagers) where repeated prime-boost regimens are not feasible. While recombinant adenovirus (rAd)-based vaccines have conferred full protection against multiple strains of Ebola after a single immunization, their efficacy is impaired by pre-existing immunity (PEI) to adenovirus. To address this important issue, a panel of formulations was evaluated by an in vitro assay for their ability to protect rAd from neutralization. An amphiphilic polymer (F16, FW ∼39,000) significantly improved transgene expression in the presence of anti-Ad neutralizing antibodies (NAB) at concentrations of 5 times the 50% neutralizing dose (ND50). In vivo performance of rAd in F16 was compared with unformulated virus, virus modified with poly(ethylene) glycol (PEG), and virus incorporated into poly(lactic-co-glycolic) acid (PLGA) polymeric beads. Histochemical analysis of lung tissue revealed that F16 promoted strong levels of transgene expression in naive mice and those that were exposed to adenovirus in the nasal cavity 28 days prior to immunization. Multiparameter flow cytometry revealed that F16 induced significantly more polyfunctional antigen-specific CD8+ T cells simultaneously producing IFN-γ, IL-2, and TNF-α than other test formulations. These effects were not compromised by PEI. Data from formulations that provided partial protection from challenge consistently identified specific immunological requirements necessary for protection. This approach may be useful for development of formulations for other vaccine platforms that also employ ubiquitous pathogens as carriers like the influenza virus.

AB - The severity and longevity of the current Ebola outbreak highlight the need for a fast-acting yet long-lasting vaccine for at-risk populations (medical personnel and rural villagers) where repeated prime-boost regimens are not feasible. While recombinant adenovirus (rAd)-based vaccines have conferred full protection against multiple strains of Ebola after a single immunization, their efficacy is impaired by pre-existing immunity (PEI) to adenovirus. To address this important issue, a panel of formulations was evaluated by an in vitro assay for their ability to protect rAd from neutralization. An amphiphilic polymer (F16, FW ∼39,000) significantly improved transgene expression in the presence of anti-Ad neutralizing antibodies (NAB) at concentrations of 5 times the 50% neutralizing dose (ND50). In vivo performance of rAd in F16 was compared with unformulated virus, virus modified with poly(ethylene) glycol (PEG), and virus incorporated into poly(lactic-co-glycolic) acid (PLGA) polymeric beads. Histochemical analysis of lung tissue revealed that F16 promoted strong levels of transgene expression in naive mice and those that were exposed to adenovirus in the nasal cavity 28 days prior to immunization. Multiparameter flow cytometry revealed that F16 induced significantly more polyfunctional antigen-specific CD8+ T cells simultaneously producing IFN-γ, IL-2, and TNF-α than other test formulations. These effects were not compromised by PEI. Data from formulations that provided partial protection from challenge consistently identified specific immunological requirements necessary for protection. This approach may be useful for development of formulations for other vaccine platforms that also employ ubiquitous pathogens as carriers like the influenza virus.

KW - adenovirus serotype 5

KW - Ebola virus

KW - formulation

KW - multifunctional CD8<sup>+</sup> T cell response

KW - nasal vaccine

KW - pre-existing immunity

UR - http://www.scopus.com/inward/record.url?scp=84938328146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938328146&partnerID=8YFLogxK

U2 - 10.1021/mp5006454

DO - 10.1021/mp5006454

M3 - Article

VL - 12

SP - 2697

EP - 2711

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 8

ER -